Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | MME | P08473 | 4/20 | 0.55 |
| ▸ | ACE | P12821 | 4/20 | 0.55 |
| ▸ | CPA1 | P15085 | 4/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439794 | 1.00 | EPHX2 (0.56) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL29069408 | 1.00 | EPHX2 (0.56) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL12678083 | 0.98 | MME (0.54) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL7257313 | 0.98 | MME (0.54) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL10933319 | 0.95 | MME (0.54) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL7258036 | 0.95 | MME (0.54) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL2076149 | 0.92 | POLB (0.55) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL2076151 | 0.92 | POLB (0.55) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL838649 | 0.88 | NPC1 (0.54) | EPHX2MMEACECPA1ACE2 | |
| SCHEMBL838650 | 0.88 | NPC1 (0.54) | EPHX2MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-03-21 | — | — | US | disclosed |
| CN-116730980-A | Compound and stereoisomer thereof, or pharmaceutically acceptable salt and application thereof | 合肥工业大学智能制造技术研究院 | 2023-09-12 | — | — | CN | disclosed |
| US-20210363207-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-11-25 | — | — | US | disclosed |
| US-20190077840-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2019-03-14 | — | — | US | disclosed |
| CN-107530405-A | Insulin analogs containing glucose-regulated conformational converters | 卡斯西部储备大学 | 2018-01-02 | — | — | CN | disclosed |
| WO-2017075349-A2 | SELECTIVE MCL-1 BINDING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20050288222-A1 | Methods for enhancing the bioavailability of a drug | HAYWARD NEIL J | 2005-12-29 | — | — | US | disclosed |
| EP-1263454-A2 | METHODS FOR ENHANCING THE BIOAVAILABILITY OF A DRUG | Praecis Pharmaceuticals Incorporated (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020142950-A1 | Methods for enhancing the bioavailability of a drug | PRAECIS PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2001058470-A2 | METHODS FOR ENHANCING THE BIOAVAILABILITY OF A DRUG | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2000010005-A1 | USE OF ANALYTICAL TRACER MOLECULES | SEDERMA (FR) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142950-A1 | Methods for enhancing the bioavailability of a drug | IAPP, VIP, FABP1 | EPHX2 867/4885MME 49/4885ACE 224/4885 |
| US-20190077840-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | EPHX2 4824/4885MME 748/4885ACE 4708/4885 |
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | EPHX2 4824/4885MME 748/4885ACE 4708/4885 |
| US-20210363207-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | EPHX2 4824/4885MME 748/4885ACE 4708/4885 |
| US-20050288222-A1 | Methods for enhancing the bioavailability of a drug | IAPP, APP, VIP | EPHX2 806/4885MME 45/4885ACE 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.